Category: news

  • Despite Canadian government woes, neuroscience should win out

    Despite Canadian government woes, neuroscience should win out

    MONTREAL — When Canada’s Conservative government presented its 2011 budget in late March, the fiscal plan didn’t contain too many surprises for science funding. Like previous budgets, the proposal offered modest increases to the country’s national research agencies and replenished the coffers of Genome Canada, its genomics and proteomics outfit. But the budget also contained a flashy and unprecedented new move: a multimillion-dollar earmark for neuroscience research.

    Under the Conservatives’ proposed scheme, the government would contribute up to C$100 million ($105 million) over several years to the Canada Brain Research Fund, a public-private partnership led by the Brain Canada Foundation in collaboration with the Canadian Association for Neuroscience and Neurological Health Charities Canada (NHCC). The government money would then be matched by funds raised from private sources by Brain Canada to support large, multidisciplinary neuroscience grants, postdoctoral fellowships and training programs.

    Read the full story at Nature Medicine(subscription required). Published online 5 May 2011.

    Magnetic Resonance Imaging scan of a head. Released under the GFDL by en:User:TheBrain on 20 May 2003.

  • Canadian research shift makes waves

    Canadian research shift makes waves

    McDougallNRC

    Agency’s focus on industry-driven projects raises concerns that basic science will suffer.

    Published in Nature, 19 April 2011.

    Canada’s largest research entity has a new focus — and some disaffected scientists. On 1 April, the National Research Council (NRC), made up of more than 20 institutes and programmes with a total annual budget larger than Can$1 billion (US$1 billion), switched to a funding strategy that downplays basic research in favour of programmes designed to attract industry partners and generate revenue. Some researchers suggest that the shift is politically driven, because it brings the agency into philosophical alignment with the governing Conservative Party of Canada, which is in the middle of an election campaign.

    The change was announced in a memo from NRC president John McDougall on 2 March, and involves the transfer of authority over 20% of the agency’s research funds and the entire Can$60-million budget for large equipment and building costs to the NRC’s senior executive committee, which will direct it towards research with a focus on economic development, rather than pure science. Until now, individual institutes have had authority over research spending. McDougall wrote that in future, 80% of the research budget will be centralized, with “curiosity and exploratory activities” to be funded by the remaining 20%.

    In Canada, most funding for academic researchers flows through agencies other than the NRC. However, with 4,700 scientists, guest researchers, technologists and support staff pursuing specialities from astrophysics to plant biotechnology at its institutes, the NRC plays a vital part in the nation’s scientific community, as a generator of original research and a service provider to government and industry. The shift away from basic science “weakens” the NRC’s labs, because they “are required to bridge two cultures — the basic and applied”, says John Polanyi, a Nobel laureate and a chemist at the University of Toronto.

    But in a follow-up memo on 24 March, McDougall said “most ‘researcher directed’ and basic work is now carried out in academic institutions. Duplicating the efforts of universities at NRC doesn’t make much sense.”

    Four proposed ‘flagship programmes’ described in the original memo, each with a marketable outcome, provide a glimpse at the direction the agency has in mind. They include developing a strain of wheat resilient to environmental stress; improving the manufacture of printable electronics; increasing domestic production of bio composite materials; and using algae to soak up carbon dioxide emissions from industry. NRC researchers have expressed concern that jobs and programmes that do not fit with the new agenda are at risk. The agency declined to comment.

    Tom Brzustowski, who studies commercialization of innovation at the University of Ottawa, says that the adjustment to the NRC’s focus will support areas that have been weak. “By focusing on the flagship programmes there is still room to do the whole spectrum of research. It’s a good strategic move,” he says.

    But the news has rekindled anxiety over how Canada’s government has been directing science funding — criticisms that have grown sharper as the federal election on 2 May approaches.

    On 22 March, the government presented its 2011 budget, which offered modest increases to the federal research councils, but did not make up for cuts in 2009 (see Nature 457, 646; 2009). The budget also included multi million-dollar investments in neuroscience and physics. Few question the quality of work that such investments would produce, but critics say that the government is exerting too much control over the country’s research, rather than allowing peer review to guide funding.

    “It’s risky to divert funds away from the granting councils, but the government does it because it looks politically better for them,” says Robert Dunn, associate director of scientific affairs at the Montreal Neurological Institute. “Peer review is the very best mechanism to ensure that the limited research resources we have are allocated to the best researchers and projects.”

    Photo: NRC Canada

  • Why blog? Because it’s the best job, ever

    Thanks to a grant from the National Association of Science Writers, the New England Science Writers has made their Jan. 19 presentation on health & science blogging freely available online.

    The panel featured:

    For more details and links, visit: http://neswonline.com.

    And a write up by organizer and freelance journalist Carol Cruzen Morton on her blog Gravity Surfing.

  • Bill to help Canadian companies ship generics has uncertain future

    Bill to help Canadian companies ship generics has uncertain future

    From Nature Medicine. Published online 7 March 2011.

    Backed by nongovernmental organizations and the generics industry, the left-of-center New Democratic Party has championed a bill that set out to improve Canada’s Access to Medicines Regime (CAMR), a law that enables drug manufacturers in the country to make generic medications for shipment to developing countries to treat illnesses such as tuberculosis and AIDS. The bill, C-393, was introduced to the House of Commons in 2009 and aimed to eliminate many of the CAMR procedures that its supporters consider unwieldy and extend the list of eligible drugs. But the bill has been so gutted that many global health advocates say they cannot support it in its current state, and it is floundering in Canada’s parliament.

    Under the existing legislation, generic manufacturers that are unable to negotiate a voluntary license from the patent holders can ask the Canadian Commissioner of Patents for a compulsory license to produce an eligible product to address public health problems in another country. If the commissioner says yes, the law then authorizes a one-time license for a named product, along with the country to which it is to be shipped and order size.

    Read the full article at Nature Medicine (subscription required).

    Photo by Takkk.

  • Cancer drugs should add months, not weeks, say experts

    From Nature Medicine. Published online 7 January 2011.

    In the last decade, the world’s drug regulatory agencies have approved dozens of new anticancer therapies for everything from lung carcinoma to skin melanoma. Some of these new drugs add months to a patient’s life. But others may offer only an extra week or two, on average, often with considerable toxicity and at a cost of thousands of dollars.

    Now experts are questioning whether these outcomes provide meaningful benefit to people’s quality of life and are urging regulatory agencies to toughen the criteria for drug approval. Such a measure would push pharmaceutical companies to modify the design of clinical trials—a move that some drug makers and doctors worry could shrink the drug market.

    Read the full article at Nature Medicine (subscription required).